Xenon Pharmaceuticals (NASDAQ: XENE) Stock Plunges After Clinical Trial Pause

• Analyst firm Wedbush lowered its price target for Xenon Pharmaceuticals due to a clinical trial pause.
• Xenon Pharmaceuticals voluntarily halted new patient enrollment for psychiatry studies involving its lead drug, azetukalner, following reports of neuropsychiatric adverse events.
• The market reacted sharply, with Xenon Pharmaceuticals stock falling 27.6% in pre-market trading, marking its worst single-day performance since 2017.

Xenon Pharmaceuticals (NASDAQ: XENE) is a clinical-stage biopharmaceutical company. It focuses on creating treatments for neurological and psychiatric disorders, such as epilepsy and depression. The company's stock is listed on the NASDAQ exchange.

On September 18, 2026, the analyst firm Wedbush lowers its price target for Xenon Pharmaceuticals to $55.00 from a previous target of $71.00. A price target is an analyst's projection of a stock's future price. At the time of the announcement, the company's stock price is $57.35.

This change in outlook follows Xenon Pharmaceuticals' announcement of a temporary pause in new patient enrollment for its psychiatry studies. The voluntary pause affects clinical trials for its lead drug, azetukalner. This drug was being developed to treat major depressive disorder and bipolar depression.

The decision to pause the trials comes after reports of neuropsychiatric adverse events. These are side effects related to mental and nervous system functions, as highlighted by Reuters. The news results in the stock experiencing its worst single-day performance since 2017.

The market's reaction is significant. In pre-market trading, shares of Xenon Pharmaceuticals fall 27.6% to $41.51. The company has a market capitalization of approximately $5.54 billion, which represents the total value of all its shares.